Opportunity
Federal Register #DEA-1720
DEA Solicits Comments on PCI Pharma Services Application to Import Controlled Substances for Research and Clinical Trials
Buyer
Drug Enforcement Administration
Posted
June 17, 2026
Respond By
July 17, 2026
Identifier
DEA-1720
NAICS
424210
This opportunity concerns the Drug Enforcement Administration (DEA) seeking public comment on an application to import controlled substances: - Government Buyer: - U.S. Department of Justice, Drug Enforcement Administration (DEA) - OEM/Vendor: - AndersonBrecon, Inc. DBA PCI Pharma Services - Products/Controlled Substances Requested: - Derivatives of Cocaine (drug code 9041) for analytical and reference standard purposes - Intermediate of Lysergic acid diethylamide (LSD, drug code 7315) as a bulk Active Pharmaceutical Ingredient - Tetrahydrocannabinols (drug code 7370) as dosage units for clinical trials - Methadone (drug code 9250) as dosage units for clinical trials - Thebaine (drug code 9333) as dosage units for clinical trials - 3,4-Methylenedioxymethamphetamine (MDMA, drug code 7405) as dosage units for clinical trials - Dimethyltryptamine (DMT, drug code 7435) as dosage units for clinical trials - Pentobarbital (drug code 2270) as dosage units for clinical trials - Unique/Notable Requirements: - Imports are strictly for analytical, reference standard, or clinical trial purposes - No authorization for commercial sale or other activities beyond those specified - DEA is soliciting comments or objections from registered bulk manufacturers and stakeholders - OEM Highlight: - AndersonBrecon, Inc. DBA PCI Pharma Services is the applicant and intended importer
Description
AndersonBrecon, Inc. DBA PCI Pharma Services has applied to be registered as an importer of basic classes of controlled substances. The company plans to import derivatives of Cocaine for analytical and reference standard purposes, an intermediate of Lysergic acid diethylamide as bulk Active Pharmaceutical Ingredient, and other listed controlled substances as dosage units to support clinical trials. No other activities for these drug codes are authorized for this registration. Comments or objections can be submitted electronically or in writing on or before July 17, 2026, and a written request for a hearing can also be filed by that date.